Table 1.

Anti-PD-1 and anti-PD-L1 efficacy in patients with wild-type NSCLC versus patients with EGFR-mutated NSCLC

Study	Treatment	EGFR-mutated n (%)	HR OS wild-type versus mutated patients who received anti-PD-1 or PD-L1
Check Mate 05744	Nivolumab versus docetaxel	82 (14%)	0.66 (0.51–0.85) versus 1.18 (0.45–2.07)
KEYNOTE-01082	Pembrolizumab versus docetaxel	86 (8%)	0.66 (0.55–0.79) versus 0.88 (0.45–1.72)
OAK83	Atezolizumab versus docetaxel	85 (10%)	0.69 (0.57–0.83) versus 1.24 (0.71–2.18)
POPLAR61	Atezolizumab versus docetaxel	18 (6%)	0.70 (0.47–1.04) versus 0.99 (0.29–3.40)
ImPOWER 15013	Atezolizumab plus bevacizumab and chemotherapy versuschemotherapy plus bevacizumab	80 (10%)	0.62 (0.52–0.74) versus 0.41 (0.22–0.78)

NSCLC, non-small cell lung cancer; OS, overall survival; PD-1, programmed cell death protein 1; PD-L1, programmed death-ligand 1.